Nanobiotix Logo

Nanobiotix

Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.

NANO | PA

Overview

Corporate Details

ISIN(s):
FR0010102145 (+2 more)
LEI:
969500667RSYIH8YL895
Country:
France
Address:
60 RUE DE WATTIGNIES, 75012 PARIS
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Nanobiotix is a late-stage clinical biotechnology company pioneering the development and commercialization of physics-based nanotherapeutics. The company's lead candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. It works by amplifying the dose and efficacy of radiotherapy within cancer cells, aiming to enhance tumor destruction while sparing surrounding healthy tissue. This approach may also prime an immune response against metastatic tumors. Nanobiotix has a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson company, to co-develop and commercialize NBTXR3, with an initial focus on head, neck, and lung cancers.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-28 15:41
Major Shareholding Notification
Franchissement de seuil
French 125.2 KB
2025-11-13 18:16
Regulatory News Service
Franchissement de seuil
French 277.7 KB
2025-11-13 17:45
Regulatory News Service
Franchissement de seuil
French 126.3 KB
2025-09-12 19:00
Declaration of Voting Results & Voting Rights Announcements
INFORMATION MENSUELLE RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS …
French 112.2 KB
2025-09-12 19:00
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
English 113.6 KB
2025-09-02 22:15
Regulatory News Service
Nanobiotix participera à la conférence investisseurs annuelle H.C. Wainwright g…
French 93.9 KB
2025-09-02 22:15
Regulatory News Service
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment …
English 69.0 KB
2025-08-11 11:29
Major Shareholding Notification
Franchissements de seuils
French 111.3 KB
2025-07-11 11:18
Major Shareholding Notification
Franchissement de seuils
French 123.4 KB
2025-07-11 11:11
Major Shareholding Notification
Franchissement de seuils
French 122.5 KB
2025-06-20 15:17
Major Shareholding Notification
Franchissement de seuils
French 123.1 KB
2025-06-20 15:07
Major Shareholding Notification
Franchissement de seuils
French 123.4 KB
2025-06-10 22:15
Declaration of Voting Results & Voting Rights Announcements
Information mensuelle relative au nombre total de droits de vote et d’actions c…
French 110.8 KB
2025-06-10 22:15
Declaration of Voting Results & Voting Rights Announcements
Voting Rights and Shares Capital of the Company
English 112.0 KB
2025-05-28 08:00
Regulatory News Service
NANOBIOTIX participera à la conférence investisseurs annuelle Jefferies Global …
French 91.4 KB

Automate Your Workflow. Get a real-time feed of all Nanobiotix filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Nanobiotix

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Nanobiotix via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-05-11 N/A Other Other 959,060 N/A

Peer Companies

CELL BIOTECH CO ., LTD Logo
A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.
South Korea
049960
Celldex Therapeutics, Inc. Logo
Develops antibody-based therapies for severe inflammatory, allergic, and autoimmune diseases.
United States of America
CLDX
Cellectar Biosciences, Inc. Logo
Late-stage biopharma developing targeted cancer therapies with a proprietary PDC delivery platform.
United States of America
CLRB
Cellectis Logo
Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.
France
ALCLS
Cellid Co., Ltd. Logo
Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.
South Korea
299660
Cellromax Science Co., Ltd. Logo
Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.
South Korea
471820
CellSeed Inc. Logo
Develops cell sheet products, culture equipment, and offers contract manufacturing services.
Japan
7776
CellSource Co.,Ltd. Logo
Processes patient-derived stem cells and PRP for regenerative therapies at medical facilities.
Japan
4880
Celltrion, Inc. Logo
A biopharma pioneer developing biosimilars and novel drugs for immunology and oncology.
South Korea
068270
Celon Pharma S.A. Logo
Researches, develops, and markets innovative drugs for oncology and neurology.
Poland
CLN

Talk to a Data Expert

Have a question? We'll get back to you promptly.